| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $19.4M | +17.3% |
| SG&A Expense | $8.2M | +18.6% |
| Operating Income | -$27.5M | -17.7% |
| Pre-tax Income | -$59.1M | -118.6% |
| Income Tax | $0 | — |
| Net Income | -$62.3M | -130.5% |
| EPS (Basic) | -$1.02 | -82.1% |
| EPS (Diluted) | -$1.02 | -82.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $8.7M | -30.7% |
| Accounts Receivable | $75K | +188.5% |
| Current Assets | $54.4M | +94.6% |
| Total Assets | $68.9M | +51.3% |
| Current Liabilities | $35.4M | +415.4% |
| Total Liabilities | $36.3M | +429.0% |
| Stockholders' Equity | $32.6M | -15.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$25.4M | -6.2% |
| Capital Expenditures | $34K | +0.0% |
| Investing Cash Flow | -$27.5M | -276.8% |
| Financing Cash Flow | $49.0M | +524.2% |
| Free Cash Flow | -$25.5M | -6.2% |